Business
HeartBeam Announces First Commercial Customer as ClearCardio Brings Groundbreaking 12-Lead ECG Technology to High-Growth Preventive Cardiology Market
Marks HeartBeam’s transition to commercial company Rapidly growing practice and highly engaged member population to enable broad adoption Enables efficient
About this update from Heartbeam, Inc.
[{"type":"text","content":"\n\nMarks HeartBeam’s transition to commercial company\n\n\n\nRapidly growing practice and highly engaged member population to enable broad adoption\n\n\n\nEnables efficient scaling of additional preventive cardiology and executive health programs\n\n\n\nEstablishes initial foothold in structured direct pay healthcare segment representing 5 million patients\n\n\n\n SANTA CLARA, Calif.--(BUSINESS WIRE)--\nHeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, announced a commercial partnership with ClearCardio™, a leading preventive cardiology practice that has served thousands of patients through advanced heart health screening and personalized prevention programs. In addition to serving as HeartBeam’s first commercial customer, ClearCardio also plans to make an investment in HeartBeam, reflecting strong strategic alignment.\n\n\nThe partnership includes an initial staged rollout to ensure a seamless patient and physician experience, and plans for broader expansion to thousands of highly engaged members across multiple U.S. geographies. ClearCardio offers its members a cardiac prevention program to monitor cardiac risk factors and will incorporate HeartBeam’s synthesized 12-lead ECG technology into the program for arrhythmia assessment.\n\n\nHeartBeam’s patented cable-free 3D ECG technology captures the heart’s electrical signals in three non-coplanar dimensions and synthesizes them into a 12-lead ECG. This allows patients to obtain a high-fidelity, clinical-grade ECG reading for their arrhythmia from the comfort of home, or wherever they happen to be, representing a new level of convenience and peace of mind.\n\n\n“ClearCardio was founded on the belief that proactive care, including earlier detection and continuous vigilance, can meaningfully change patient outcomes,” said John Osborne, MD, PhD, Chief Medical Officer of ClearCardio, “HeartBeam’s synthesized 12-lead ECG technology for arrhythmia assessments fits directly into that mission by giving our patients an unprecedented ability to capture meaningful cardiac data whenever symptoms occur while being connected directly to our physicians. This is a major step forward in preventive cardiology.”\n\n\nThis collaboration highlights HeartBeam’s fit within a premium, innovation-first segment where p...